Jane Street Group, LLC Gamida Cell Ltd. Transaction History

Jane Street Group, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.04 - $0.46 $2,316 - $26,634	57,900 Added 299.49%	77,233 $3,000
Q4 2023 Feb 14, 2024	BUY	$0.25 - $1.02 $4,833 - $19,719	19,333 New	19,333 $7,000
Q2 2023 Aug 14, 2023	SELL	$0.73 - $2.37 $14,181 - $46,041	-19,427 Reduced 36.79%	33,372 $64,000
Q1 2023 May 15, 2023	BUY	$0.68 - $1.71 $18,557 - $46,667	27,291 Added 106.99%	52,799 $42,000
Q4 2022 Feb 14, 2023	BUY	$1.15 - $2.1 $29,334 - $53,566	25,508 New	25,508 $32,000
Q4 2021 Feb 15, 2022	SELL	$2.2 - $4.46 $80,223 - $162,633	-36,465 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$3.85 - $6.44 $140,390 - $234,834	36,465 New	36,465 $143,000

2.2K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.